ArticleFrontiers in pharmacology2024
Chemokine ligand 14 correlates with immune cell infiltration in the gastric cancer microenvironment in predicting unfavorable prognosis.
Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effectiveness and safety of early rehabilitation in the prevention of postoperative complications after craniotomy: a systematic review and meta-analysis.Neurosurgical review · 2026Pooled it
- KRT13 Drives Pancreatic Cancer Malignancy Via the PI3K/AKT-PPARG Axis While Enhancing Sensitivity to Navitoclax.Medical science monitor : international medical journal of experimental and clinical research · 2026Article
- Efficacy of cemiplimab in biomarker defined subgroups of non-small cell lung cancer: a systematic review and meta-analysis.Journal of thoracic disease · 2026Article
- CXCL8 producing macrophages shape gastric cancer outcomes.Discover oncology · 2026Article
- Chikungunya: global epidemiology, clinical spectrum, and vector control-lessons for China from the 2025 Guangdong outbreak.Archives of toxicology · 2026Review
- Peripheral blood mononuclear cell gene expression signatures predict long-term survivorship in canine DLBCL.Scientific reports · 2026Article
- Metagenomic next-generation sequencing reveals microbial community characteristics during acute exacerbations of interstitial pneumonia and their associations with clinical phenotypes.Frontiers in cellular and infection microbiology · 2026Article
- Molecularly engineered BODIPY photosensitizers for combined cancer phototherapy and immunotherapy.Frontiers in pharmacology · 2026Review
- Integrative Multiomics Analysis Identifies a Novel Gene Signature That Predicts Chemotherapy Resistance and Poor Survival in Osteosarcoma.Human mutation · 2026Article
- Targeting regulated cell death pathways in lung cancer: mechanisms, therapeutic strategies, and clinical translation.Frontiers in immunology · 2026Review
- Melatonin: a promising therapy to combat type 2 airway inflammation via MT1-Sirt1 pathway.Frontiers in pharmacology · 2026Article
- Investigating the role of MYLK2 in breast cancer prognosis and assessing its clinical application value.Scientific reports · 2025Article
- Mapping the landscape of ovarian metastases of gastric cancer: insights, trends, and emerging perspectives.World journal of surgical oncology · 2025Review
- Article
- DCUN1D5 is a novel potential biomarker for predicting the prognosis of bladder cancer.Discover oncology · 2025Article
- Tumor habitat-derived radiomics features in pretreatment CT scans for predicting concurrent chemoradiotherapy responses in nasopharyngeal carcinoma: a retrospective study.Quantitative imaging in medicine and surgery · 2025Article
- Transumbilical single-site laparoscopic resection of splenic papillary angioendothelioma in a pediatric patient: a rare case report and review of literature.Frontiers in oncology · 2025Article
- Identification of Plasma Protein Biomarkers and Drug Targets for Hematologic Malignancies by Proteome-wide Mendelian Randomization.Journal of Cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Gastric cancer (GC) is the world's third-leading cause of cancer-related mortality; the prognosis for GC patients remains poor in terms of a lack of reliable biomarkers for early diagnosis and immune therapy response prediction. Here, we aim to discover the connection between chemokine ligand 14 (CCL14) expression in the gastric tumor microenvironment (TME) and its clinical significance and investigate its correlation with immune cell infiltration. Methods: We assessed CCL14 mRNA expression and its interrelation with tumor-infiltrating immune cells (TILs) using bioinformatics analysis in gastric cancer. CCL14 protein expression, TILs, and immune checkpoints were detected by multiple immunohistochemistry analyses in gastric cancer tissue microarrays. Then, we conducted statistics analysis to determine the association between CCL14-related patient survival and immune cell infiltration ( Results: We found that the CCL14 protein was separately expressed in the carcinoma cells and TILs in stomach cancer tissues. The CCL14 protein was related to tumor differentiation and tumor depth and positively correlated with the presentation of LAG3 and PD-L1 in gastric cancer cells. In addition, the CCL14 protein in the TILs of gastric cancer tissues was related to Lauren's type cells, T cells (CD4 Conclusion: Our study illustrated that CCL14 is a poor prognosis biomarker in gastric cancer, which may be associated with the potential for immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.